Kynamro Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kynamro market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historic period can be attributed to the increasing prevalence of familial hypercholesterolemia (HoFH), rising global obesity rates, the expansion of patient advocacy campaigns, increased healthcare expenditure, and positive outcomes from clinical trials.

The anticipated growth during the forecast period is driven by the rising prevalence of cardiovascular diseases, higher diagnosis rates, an expanding geriatric population, increased adoption of personalized medicine, and growing R&D activities. Key trends expected during the forecast period include advancements in RNA therapeutics, innovations in genetic testing technologies, a shift towards personalized medicine, technological progress in treatment options, and the application of AI in drug discovery.

The increasing prevalence of cardiovascular disease is expected to drive the growth of the kynamro market in the coming years. Cardiovascular disease refers to a range of conditions that affect the heart and blood vessels, often leading to complications such as heart attacks, strokes, and hypertension. The rise in cardiovascular disease prevalence is linked to factors such as unhealthy diets, physical inactivity, smoking, excessive alcohol use, and increasing rates of obesity and diabetes. Kynamro helps manage cholesterol levels by blocking the production of a protein that contributes to cholesterol buildup, reducing the long-term risk of cardiovascular disease. For example, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported 14,900 doctor-certified deaths from coronary heart disease (CHD) in 2022, up from 14,100 in 2021. Therefore, the growing prevalence of cardiovascular disease is fueling the growth of the kynamro market.

The rise in personalized medicine is anticipated to boost the growth of the kynamro market in the future. Personalized medicine involves tailoring healthcare treatments to an individual’s unique genetic profile, environment, and lifestyle. Factors driving demand for personalized medicine include advances in genetic research, improved disease understanding at the molecular level, and enhanced diagnostic tools. Kynamro exemplifies personalized medicine by providing a targeted treatment for individuals with homozygous familial hypercholesterolemia (HoFH), directly addressing the genetic causes of elevated LDL cholesterol. This customized approach improves cholesterol management, particularly for patients unresponsive to standard therapies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. Thus, the growing adoption of personalized medicine is driving the kynamro market forward.

The rising prevalence of hypercholesterolemia is significantly contributing to the growth of the kynamro market. Hypercholesterolemia is a medical condition characterized by abnormally high cholesterol levels in the blood, often caused by genetic conditions, unhealthy diets, lack of physical activity, diabetes, and hypothyroidism. Kynamro is effective in reducing LDL cholesterol levels in patients with familial hypercholesterolemia or those inadequately managed by other treatments, making it an essential tool for managing hypercholesterolemia. For example, in December 2023, the Australian Bureau of Statistics, an Australian government agency, reported that approximately 8.4% of the population, or 2.1 million people, had high cholesterol in 2022. The prevalence varied by age, affecting 1.1% of individuals aged 18-34 and 29% of those aged 75 and older. As a result, the rising prevalence of hypercholesterolemia is a key driver of growth in the kynamro market.

The key company operating in the kynamro market is Ionis Pharmaceuticals Inc.

North America was the largest region in the kynamro market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in kynamro report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kynamro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kynamro is a medication specifically designed to treat individuals with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to dangerously high cholesterol levels. It functions by inhibiting the production of apolipoprotein B-100, a vital protein involved in the formation of low-density lipoprotein (LDL) cholesterol. By lowering LDL cholesterol, Kynamro aids in managing cholesterol levels in patients who have not achieved adequate control with other treatments. It is used in conjunction with other lipid-lowering therapies to enhance cholesterol management in these patients.

The primary types of kynamro formulations include injectable formulations (subcutaneous) and pre-filled syringes or auto-injectors. The subcutaneous injectable formulation provides consistent and controlled drug release, offering convenience for self-administration by patients with genetic cholesterol disorders. Kynamro is used for various indications, including the treatment of homozygous familial hypercholesterolemia (HoFH), management of elevated LDL-C levels, and other conditions across multiple patient demographics, such as pediatric, adult, and geriatric patients. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies. End users include hospitals, specialty clinics, cardiovascular treatment centers, and home healthcare providers.

The kynamro market research report is one of a series of new reports that provides kynamro market statistics, including the kynamro industry global market size, regional shares, competitors with the kynamro market share, detailed kynamro market segments, market trends, and opportunities, and any further data you may need to thrive in the kynamro industry. This kynamro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kynamro market consists of sales of kynamro vials, syringes, needles, and mipomersen sodium (active ingredient). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.